Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$248.060.0%$226.15$184.63▼$261.64$438.31B0.39.03 million shs4.14 million shsMRKMerck & Co., Inc.$123.93+0.3%$119.12$76.66▼$130.29$305.12B0.1910.67 million shs5.19 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.02%-2.63%+9.02%+17.96%+28.98%MRKMerck & Co., Inc.+0.17%-2.25%+4.10%+3.33%+48.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$248.060.0%$226.15$184.63▼$261.64$438.31B0.39.03 million shs4.14 million shsMRKMerck & Co., Inc.$123.93+0.3%$119.12$76.66▼$130.29$305.12B0.1910.67 million shs5.19 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.02%-2.63%+9.02%+17.96%+28.98%MRKMerck & Co., Inc.+0.17%-2.25%+4.10%+3.33%+48.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.84Moderate Buy$266.247.33% UpsideMRKMerck & Co., Inc. 2.70Moderate Buy$133.948.08% UpsideCurrent Analyst Ratings BreakdownLatest MRK and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026ABBVAbbVie UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$230.00 ➝ $260.007/13/2026ABBVAbbVie BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$258.00 ➝ $300.007/13/2026MRKMerck & Co., Inc. JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$135.00 ➝ $140.007/13/2026MRKMerck & Co., Inc. BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$135.00 ➝ $142.007/13/2026MRKMerck & Co., Inc. GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $145.007/10/2026ABBVAbbVie Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $295.007/10/2026ABBVAbbVie Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$234.00 ➝ $276.007/10/2026ABBVAbbVie Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$260.00 ➝ $280.007/9/2026ABBVAbbVie GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$249.00 ➝ $261.007/9/2026ABBVAbbVie JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $280.007/9/2026MRKMerck & Co., Inc. Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$112.00 ➝ $113.00(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$61.16B7.17$15.14 per share16.38($1.83) per share-135.55MRKMerck & Co., Inc.$65.01B4.71$11.46 per share10.81$21.22 per share5.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03122.2015.470.815.79%-576.45%13.39%7/31/2026 (Estimated)MRKMerck & Co., Inc.$18.25B$3.5534.9112.522.6513.59%27.55%10.73%8/4/2026 (Estimated)Latest MRK and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026MRKMerck & Co., Inc.$2.15N/AN/AN/A$16.40 billionN/A7/31/2026Q2 2026ABBVAbbVie$3.71N/AN/AN/A$16.78 billionN/A4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.922.79%+6.80%340.89%53 YearsMRKMerck & Co., Inc.$3.402.74%+5.75%95.77%14 YearsLatest MRK and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/18/2026ABBVAbbViequarterly$1.733.19%7/15/20267/15/20268/14/20265/26/2026MRKMerck & Co., Inc.quarterly$0.852.96%6/15/20266/15/20267/8/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68MRKMerck & Co., Inc.1.021.301.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%MRKMerck & Co., Inc.0.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableMRK and ABBV HeadlinesRecent News About These CompaniesLegacy Capital Group California Inc. Sells 17,121 Shares of Merck & Co., Inc. $MRK1 hour ago | marketbeat.comMerck & Co., Inc. $MRK Shares Sold by Principal Financial Group Inc.1 hour ago | marketbeat.comBryn Mawr Trust Advisors LLC Has $26.75 Million Stock Holdings in Merck & Co., Inc. $MRK3 hours ago | marketbeat.comDiversify Wealth Management LLC Raises Position in Merck & Co., Inc. $MRK3 hours ago | marketbeat.comMerck & Co., Inc. $MRK Stake Trimmed by Avantax Planning Partners Inc.4 hours ago | marketbeat.comMerck (MRK) Stock Looks Like A Bargain At This PriceJuly 13 at 6:40 PM | finance.yahoo.comFDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder CancerJuly 13 at 1:39 PM | finance.yahoo.comCosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in GreeceJuly 13 at 1:39 PM | finance.yahoo.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) StockJuly 13 at 12:11 PM | marketbeat.comFDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder CancerJuly 13 at 12:11 PM | zacks.comMerck & Co., Inc. (NYSE:MRK) Given New $142.00 Price Target at BMO Capital MarketsJuly 13 at 9:11 AM | marketbeat.comWhy Merck Stock Is in the Spotlight TodayJuly 13 at 9:00 AM | benzinga.comMerck & Co., Inc. (NYSE:MRK) Price Target Raised to $145.00July 13 at 8:47 AM | marketbeat.comWhy Is Merck (NYSE:MRK) in S&P 500 Focus After FDA Approval?July 13 at 8:38 AM | kalkinemedia.comKImmutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004July 13 at 8:38 AM | finance.yahoo.comParr Mcknight Wealth Management Group LLC Has $2.98 Million Stock Position in Merck & Co., Inc. $MRKJuly 13 at 6:08 AM | marketbeat.comTriglav Investments D.O.O. Buys 57,869 Shares of Merck & Co., Inc. $MRKJuly 13 at 6:00 AM | marketbeat.comMerck & Co., Inc. $MRK Shares Acquired by J. Safra Sarasin Holding AGJuly 13 at 5:59 AM | marketbeat.comMerck & Co., Inc. $MRK Shares Purchased by Teachers Retirement System of The State of KentuckyJuly 13 at 5:51 AM | marketbeat.comMerck & Co., Inc. $MRK Stock Holdings Boosted by Procyon Advisors LLCJuly 13 at 5:43 AM | marketbeat.comCORDA Investment Management LLC. Has $51.43 Million Position in Merck & Co., Inc. $MRKJuly 13 at 4:07 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRK and ABBV Company DescriptionsAbbVie NYSE:ABBV$248.06 -0.02 (-0.01%) Closing price 07/13/2026 03:59 PM EasternExtended Trading$247.86 -0.21 (-0.08%) As of 07:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Merck & Co., Inc. NYSE:MRK$123.93 +0.39 (+0.32%) Closing price 07/13/2026 03:59 PM EasternExtended Trading$123.94 +0.00 (+0.00%) As of 07:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Analysts See Major Upside for These 5 Stocks One Short- and One Long-Term ETF for Quantum Computing Bulls Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
